MEK inhibitors in oncology: a patent review (2015-Present)

References

• Issa AM. Personalized Medici ne and the Practice of Medicine in the 21st Century. Mcgill J Med. 2007;10(1):53–57.
   PubMedGoogle Scholar
• PMI Cohort Program announces new name: the All of Us Research. National Institute of Health, U.S. 2016. [accessed 02.Dec.2016] Available from:https://www.nih.gov/AllofUs-research-program/pmi-cohort-program-announces-new-name-all-us-research-program
   Google Scholar
• Heppt MV, Tietze JK, Graf SA, et al. Combination therapy of melanoma using kinase inhibitors. Curr Opin Oncol. 2015;27(2):134–140.
   PubMed Web of Science ®Google Scholar
• Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314–341.
   PubMed Web of Science ®Google Scholar
• Qazi AK, Hussain A, Hamid A, et al. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies. Anticancer Agents Med Chem. 2013;13(10):1552–1564.
   PubMed Web of Science ®Google Scholar
• Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Oncol Res Treat. 2003;25(6):511–518.
   Web of Science ®Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310.
   PubMed Web of Science ®Google Scholar
• Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer. 2003;104(5):527–532.
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10–24.
   PubMed Web of Science ®Google Scholar
• Pelekanou V, Kampa M, Kafousi M, et al. Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer. 2008;8:76.
   PubMed Web of Science ®Google Scholar
• Pathway Central: Ras Pathway, SABiosciences, Qiagen. [cited 2017 Jan 27]. Available from: http://www.sabiosciences.com/pathway.php?sn=Ras_Pathway
   Google Scholar
• Mendoza MC, Emrah EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328.
   PubMed Web of Science ®Google Scholar
• Lodish H, Berk A, Zipursky SL, et al. Receptor tyrosine kinases and ras. Section 20.4-Molecular Cell Biology. 4th ed. New York: W. H. Freeman and Company; 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21475/
   Google Scholar
• Castellano E, Downward J. RAS interaction with PI3K more than just another effector pathway. Genes Cancer. 2011;2(3):261–274.
   PubMedGoogle Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875–885.
   PubMed Web of Science ®Google Scholar
• Rajalingam K, Schreck R, Rapp UR, et al. Ras oncogenes and their downstream targets. Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research. 2007;1773:1177–1195.
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. Ras history: the saga continues. Ras History, Small Gtpases. 2010;1(1):2–27.
   PubMedGoogle Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467.
   PubMed Web of Science ®Google Scholar
• Mark GE, Rapp UR. Primary structure of v-raf: relatedness to the src family of oncogenes. Sci. 1984;224(4646):285–289.
   PubMed Web of Science ®Google Scholar
• Jansen HW, Rückert B, Lurz R, et al. Two unrelated cell-derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. Embo J. 1983;2(11):1969.
   PubMed Web of Science ®Google Scholar
• Avruch J, Zhang XF, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci. 1994;19(7):279–283.
   PubMed Web of Science ®Google Scholar
• Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res. 1999;253(1):34–46.
   PubMed Web of Science ®Google Scholar
• Schreck R, Rapp UR. Raf kinases: oncogenesis and drug discovery. Int J Cancer. 2006;119(10):2261–2271.
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4(4):677–685.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Seeber S. Raf kinase inhibitors in oncology. Oncol Res Treat. 2005;28(2):101–107.
   Web of Science ®Google Scholar
• Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 2005;5(4):350–356.
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313–319.
   PubMed Web of Science ®Google Scholar
• Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell. 1996;87(4):629–638.
   PubMed Web of Science ®Google Scholar
• Nantel A, Huber M, Thomas DY. Localization of endogenous Grb10 to the mitochondria and its interaction with the mitochondrial-associated Raf-1 pool. J Biol Chem. 1999;274(50):35719–35724.
   PubMed Web of Science ®Google Scholar
• Yuryev A, Ono M, Goff SA, et al. Isoform-specific localization of A-RAF in mitochondria. Mol Cell Biol. 2000;20(13):4870–4878.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Data Portal. National Cancer Institute. National Institutes of Health, USA. [cited 2016 Nov 7]. Available from: https://tcga-data.nci.nih.gov/docs/publications/tcga/?
   Google Scholar
• Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nat. 2010;464(7287):431–435.
   Web of Science ®Google Scholar
• Zhou J, Wu Z, Wong G, et al. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017;8:13897.
   PubMed Web of Science ®Google Scholar
• Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3(7):742–750.
   PubMed Web of Science ®Google Scholar
• Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17(5):989–1000.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23(23):5281–5293.
   PubMed Web of Science ®Google Scholar
• Trujillo JI. MEK inhibitors: a patent review 2008–2010. Expert Opin Ther Pat. 2011;21(7):1045–1069.
   PubMed Web of Science ®Google Scholar
• Novartis. Compounds and compositions as inhibitors of MEK. US20160136150A1; 2016.
   Google Scholar
• Shanghai Hengrui Pharm Co Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof. EP3061747; 2016.
   Google Scholar
• Shanghai Kechow Pharma Inc. Benzoheterocyclic compounds and use thereof. US20160235721; 2016.
   Google Scholar
• Array BioPharma, Inc. Preparation of and formulation comprising a MEK inhibitor US20160168103A1; 2016.
   Google Scholar
• Ardea Biosciences Inc. N-(arylamino)sulfonamide derivative comprising MEK inhibitor polymorphous form, and composition, use method and method for preparing the same. JP2015078199; 2015.
   Google Scholar
• The Asan Foundation. Substituted pyridinone compounds as MEK inhibitors. US20160108041A1; 2016.
   Google Scholar
• Lupin Ltd. Pyridopyrimidine derivatives as MEK inhibitors. WO2016035008A1; 2016.
   Google Scholar
• Exelixis. MEK inhibitors and methods of their use. US20150141399A1; 2015.
   Google Scholar
• Allomek Therapeutics. Novel MEK inhibitors for treating cardiomyopathies and related conditions. US20150250762A1; 2015.
   Google Scholar
• Asana Biosciences. Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR pathways. EP2984088; 2016.
   Google Scholar
• Jiangsu Hengrui Medicine Co Ltd. p-toluenesulfonate for mek kinase inhibitor, and crystal form thereof and preparation method therefor. WO2016155473; 2016.
   Google Scholar
• The Regents of the University of Michigan. Dual MEK/PI3K inhibitors and therapeutic methods using the same. US20160002212; 2016.
   Google Scholar
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Pharmaceutical composition of MEK inhibitor and preparation method thereof. WO2016188472; 2016.
   Google Scholar
• Kyoto University. Agent for preventing and/or treating amyotrophic lateral sclerosis. WO2016114322A1; 2016.
   Google Scholar
• Tyrnovo Ltd. Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer. WO2016125169; 2016.
   Google Scholar
• Stichting Het Nl Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis. Combinations of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-MUTANT LUNG CANCER and KRAS-mutant colon cancer. EP2968564; 2016.
   Google Scholar
• Novartis. Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway US20150105417 (2015).
   Google Scholar
• Novartis. Pharmaceutical combinations. US20150306101; 2015.
   Google Scholar
• Genentech. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases. US20150111869A1 (2015).
   Google Scholar
• Genentech. Compositions for treating cancer using PD-1 AXIS binding antagonists and MEK inhibitors. WO2016011160 (2016).
   Google Scholar
• The board of regents of the University of Texas system. Treatment for melanoma. WO2015009591 (2015).
   Google Scholar
• Hoffmann-La Roche. Combinations of PI3K inhibitor and MEK inhibitor. JP2015038110 (2015).
   Google Scholar
• Sanofi. Methods for treating cancer using PI3K inhibitor and MEK inhibitor. US20150031882 (2015).
   Google Scholar
• Stichting Het Nederlands Kanker Instituut. P90RSK in combination with RAF/ERK/MEK. WO2015041534 (2015).
   Google Scholar
• Takeda Pharmaceutical. Administration of a RAF inhibitor and a MEK inhibitor in the treatment of melanoma. EP2830664 (2015).
   Google Scholar
• GlaxoSmithKline. Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors. US20150111904 (2015).
   Google Scholar
• Novartis. Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer. US20160367662; 2016.
   Google Scholar
• Novartis. Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRAF inhibitor. US20160089434A1(2016).
   Google Scholar
• Combination therapy of a MEK inhibitor and IGF1R inhibitor. CN104487089 (2015).
   Google Scholar
• Combination. CN104382906 (2015).
   Google Scholar
• Memorial Sloan-Kettering Cancer Center. Treatment of H-RAS driven tumors. WO2015164862 (2015).
   Google Scholar
• The Regents of The University of California. Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use. SG11201507477X (2015).
   Google Scholar
• Univ Tennessee Res Foundation. Compounds for treatment of cancer. EP2964028 (2016).
   Google Scholar
• Merck. Compositions and methods for MEK inhibitor combination therapy in the treatment of cancer. WO2016014390A1 (2016).
   Google Scholar
• Novartis. Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer. EP3079698 (2016).
   Google Scholar
• Biomed Valley Discoveries Inc. Cancer treatments using combinations of MEK type 1 and ERK inhibitors. US20160310477 (2016).
   Google Scholar
• Biomed Valley Discoveries Inc. Cancer treatments using combinations of type 2 MEK and ERK inhibitors. US20160367539; 2016.
   Google Scholar
• Crystal Pharmatech Co Ltd. CDK inhibitor, eutectic crystal of MEK inhibitor, and preparation method therefor. WO2016155670 (2016).
   Google Scholar
• Merrimack Pharmaceuticals Inc. Combination therapies comprising Anti-Erbb3 agents. US20160326262 (2016).
   Google Scholar
• Verastem Inc. Methods and compositions for treating abnormal cell growth. US20160346282; 2016.
   Google Scholar
• Garraway LA, Emery C, Garcia-Echeverria C MEK Mutations Conferring Resistance to MEK Inhibitors. US20150346204A1(2015).
   Google Scholar
• Massachusetts Institute of Technology. Methods of Reducing Kinase Inhibitor Resistance. US20160067250A1 (2016).
   Google Scholar
• Crown Bioscience. Methods for determining responsiveness to MEK/ERK inhibitors. WO2015149721A1 (2015).
   Google Scholar
• Bayer Pharma. Biomarkers for determining effective response of treatments of hepatocellular carcinoma (HCC) patients. WO2013178581A1(2016).
   Google Scholar
• Garraway LA, Emery C, Wagle N MEK1 Mutation Conferring Resistance to RAF and MEK. Inhibitors US20160216266 (2016).
   Google Scholar
• Memorial Sloan-Kettering Cancer Center. DDX43 as a biomarker of resistance to MEK1/2 inhibitors. 2015035146A2 (2015).
   Google Scholar
• Yonsei University. Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same. US20160346329; 2016.
   Google Scholar
• Grilley-Olson JE, Bedard PL, Fasolo A, et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs. 2016;34(6):740–749.
   PubMed Web of Science ®Google Scholar
• Duncan KE, Chang LY, Patronas M. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye. 2015;29(8):1003–1012.
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, LoRusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22(22):4456–4462.
   PubMed Web of Science ®Google Scholar